Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 1236Neoplasms 1040Carcinoma, Non-Small-Cell Lung 861Prostatic Neoplasms 692Colorectal Neoplasms 614Lung Neoplasms 578Neoplasm Metastasis 439Multiple Myeloma 425Leukemia, Myeloid, Acute 401Pancreatic Neoplasms 376Ovarian Neoplasms 364Melanoma 320Carcinoma, Hepatocellular 288Recurrence 276Squamous Cell Carcinoma of Head and Neck 275Brain Neoplasms 266Glioblastoma 247Head and Neck Neoplasms 244Stomach Neoplasms 239Carcinoma, Renal Cell 228Precursor Cell Lymphoblastic Leukemia-Lymphoma 227Lymphoma 225Triple Negative Breast Neoplasms 219Hematologic Neoplasms 209Endometrial Neoplasms 209Urinary Bladder Neoplasms 202Lymphoma, Non-Hodgkin 197Uterine Cervical Neoplasms 194Sarcoma 190Glioma 190

Interventions

enzalutamide 1abiraterone 1Prednisone 1Goserelin 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Castrate Sensitive Prostate Cancer × 90 days × Clear all
NCT03860987 2026-05-22

Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
12 enrolled
Genitourinary

Castrate Sensitive Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡